Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal ImpairmentANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52022-04-193OA
PA5001 gene involves in swimming motility and biofilm formation in Pseudomonas aeruginosaMICROBIAL PATHOGENESISIF3.52020-07-019PREAI
A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosaCLINICAL MICROBIOLOGY AND INFECTIONIF8.52019-07-0117OAAI
Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial AgentsANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52019-05-0145OAAI
Dosage Considerations for Canakinumab in Children With Periodic Fever SyndromesCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52019-01-2813PREAI
A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosaJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62018-02-0324OAAI
Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection modelJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62017-01-1025OAAI
In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organismsJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62016-04-2135OAAI
Pharmacokinetics and pharmacodynamics in antibiotic dose optimizationEXPERT OPINION ON DRUG METABOLISM & TOXICOLOGYIF3.42015-12-1444PREAI
A novel regulator PA5022 (aefA) is involved in swimming motility, biofilm formation and elastase activity of Pseudomonas aeruginosaMICROBIOLOGICAL RESEARCHIF6.92015-07-0120PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向